Previous 10 | Next 10 |
2023-10-13 10:19:48 ET Summary Cassava Sciences faces regulatory and reputational challenges, specifically regarding allegations of scientific misconduct related to its Alzheimer's drug, simufilam. Despite a strong balance sheet, heightened R&D expenses and a complex regulator...
2023-10-13 09:00:58 ET Summary A leaked report by The City University of New York was published yesterday alleging research misconduct by neuroscientist Dr. Hoau-Yan Wang involved in several simufilam-related preclinical publications. Loss of raw research material (a red flag) has...
2023-10-13 08:27:23 ET More on Momentus, Phio Pharmaceuticals, etc. Momentus Inc. (MNTS) Q2 2023 Earnings Call Transcript Wheeler REIT: Gearing Up For Sharemageddon Momentus to provide orbital delivery services for RIDE! Space Momentus prices $5M stock offeri...
2023-10-13 07:04:10 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: Earnings Kickoff
2023-10-13 02:05:00 ET Cassava Sciences (NASDAQ: SAVA) stock price will be in the spotlight on Friday after the shares crumbled by over 38% in the extended hours. The shares crashed by more than 76% from the all-time high and moved to the lowest level since January 2021. Its market cap ...
CUNY’s report makes no findings of data manipulation. The “ egregious misconduct ” cited in the report relates to internal record-keeping failures at CUNY. CUNY’s report finds that internal record-keeping failures “ prevented us...
2023-10-12 18:25:44 ET Cassava Sciences ( NASDAQ: SAVA ) plummeted 38% in after-hours trading Thursday afternoon after a report that a researcher working on behalf of the company was found to have engaged in scientific misconduct in regards to data on the company prized Alzheime...
2023-10-11 09:47:34 ET Summary The Alzheimer's Disease space is highly volatile, with stock prices reacting to positive or negative data from other companies in the sector. Cassava Sciences, Inc. experienced a correction after initial gains, highlighting the need for caution in th...
2023-10-10 08:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-10-06 15:13:30 ET Shares of Cassava Sciences (NASDAQ: SAVA) were up 14.9% for the week, according to data provided by S&P Global Market Intelligence . The healthcare stock closed at $16.64 last week, fell to a 52-week low of $16.40, and then rose to as high as $19.3...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...